Information Provided By:
Fly News Breaks for June 17, 2019
AMAG
Jun 17, 2019 | 06:01 EDT
Barclays analyst Balaji Prasad believes the risk/reward on Amag Pharmaceuticals shares is favorable into the June 23 FDA action date for Vyleesi. The analyst's $19 price target incorporates an 80c contribution from Vyleesi after adjusting for risk. He assumes a 25% launch probability for the U.S. market and a 20% launch probability for the European market. Prasad, however, views these assumptions as conservative and reiterates an Overweight rating on Amag. Vyleesi is a melanocortin 4 receptor agonist designed to be an on-demand therapy used in anticipation of sexual activity and self-administered by premenopausal women in the thigh or abdomen via a single-use subcutaneous auto-injector, the analyst points out.
News For AMAG From the Last 2 Days
There are no results for your query AMAG